Abstract
The EZH2 gene is a homolog of the Drosophila Polycomb group (PcG) gene enhancer of zest, a crucial regulator of homeotic gene expression. Several lines of evidence suggest a critical role for the EZH2 protein during normal and perturbed development of the haematopoietic and central nervous systems. Indeed, the EZH2 protein has been shown to associate with the Vav proto-oncoprotein and with the XNP protein, the product of a mental retardation gene. The EZH2 gene was previously reported to be located on chromosome 21q22 and was proposed as a candidate gene for some characteristics of the Down syndrome phenotype. We report here the genomic structure and fine mapping of the EZH2 gene. We demonstrate that the functional gene actually maps to chromosome 7q35 and that the sequence previously isolated from a chromosome 21 cosmid corresponds to a pseudogene. Finally, the nature of the EZH2 protein and its mapping to the critical region for malignant myeloid disorders lead us to propose the EZH2 gene is involved in the pathogenesis of 7q35–q36 aberrations in myeloid leukaemia.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cardoso, C., Mignon, C., Hetet, G. et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 8, 174–180 (2000). https://doi.org/10.1038/sj.ejhg.5200439
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejhg.5200439
Keywords
This article is cited by
-
EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4
Hereditas (2023)
-
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Journal of Hematology & Oncology (2022)
-
Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
Journal of Cancer Research and Clinical Oncology (2022)
-
EZH2: a novel target for cancer treatment
Journal of Hematology & Oncology (2020)
-
Down syndrome: from the age of characterization to the era of curative approach
The Nucleus (2017)